Trial · NCT04826510
Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression
NCT04826510, Phase 4, Unknown, Shanghai Mental Health Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression. Trials, record NCT04826510. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04826510
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression
- NCT number
- NCT04826510
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 189 participants, estimated
- Lead sponsor
- Shanghai Mental Health Center
- Conditions
- Depressive Disorder
- Interventions
- Perospirone hydrochloride tablets, Lithium carbonate + perospirone hydrochloride, Lithium Carbonate Pill
- First posted
- 2021-04-01
- Last updated
- 2021-04-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Global Impression Scale-Bipolar Disorder Scale (CGI-BP-S) score | Change from baseline at 2,4,8 week. | The investigators adopt the clinical General Impression Scale - Bipolar Disorder Scale (CGI-BP-S) score to analyze the scores of the subjects in different periods. |
| Primary | Hamilton Depression Scale (HAMD-17) score | Change from baseline at 2,4,8 week. | The investigators adopt the Hamilton Depression Scale (HAMD-17) score to judge the subjects' depression. Starting points: Hamilton Depression Scale (HAMD-17)) ≥2, clinical remission: Hamilton Depression Scale (HAMD-17)) \<7. |
| Secondary | Young's Manic Rating Scale (YMRS) score | Change from baseline at 2,4,8 week. | Young's Manic Rating Scale (YMRS) was used to determine the degree of mania in the subjects. Initial score: Young's Manic Rating Scale (YMRS) score ≤12; Clinical remission: Young's Manic Rating Scale (YMRS) score ≤5. |
| Secondary | Montreal Cognitive Assessment Scale (MoCA) score | Change from baseline at 8 week. | The investigators adopt the Montreal cognitive assessment scale (MoCA) score to judge whether the subjects with normal cognition and affect its subsequent different drugs. |
| Secondary | Wisconsin Card Sorting Test (WCST-128) score | Change from baseline at 8 week. | The investigators used the Wisconsin Card Sorting Test (WCST-128) score to determine whether the subjects had normal cognition. Reference value: total response number \< 60: indicating cognitive abnormalities; Incorrect response number \> 45: indicates cognitive abnormality |
| Secondary | WISC score for Children | Change from baseline at 8 week. | WISC Score for Children was used to determine whether subjects' IQ was affected by their disease. Reference value: 1. Low: Total IQ score ≤90; 2. Normal: Total IQ score is 90-110; High IQ: total IQ score ≥110 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Card Sorting Test (Berg) | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04826510
GET https://conductscience.org/api/trials/v1/NCT04826510/registered